Next 10 |
2024-07-12 10:50:24 ET Read the full article on Seeking Alpha For further details see: These are the weight loss drug stocks with the most upside - SA Sentiment Survey
2024-07-12 04:12:28 ET More on Amgen Amgen: Biotech Leader Riding High On Obesity Drug Euphoria (Downgrade) Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum Amgen: You Haven't Seen Anything Yet Lilly, Novo Nordisk to dominate weight lo...
2024-07-01 12:39:36 ET Summary Ventyx Biosciences, Inc. is focusing on advancing VTX3232 for obesity and Parkinson's, with early but promising preclinical results in obesity. The drug VTX3232 has shown potential in preclinical trials, but its application in Parkinson’s face...
A look at the top 10 most actives in the United States Freight Technologies Inc. (FRGT) rose 10.4% to $0.6899 on volume of 220,478,071 shares Nauticus Robotics Inc. (KITT) rose 23.2% to $0.17 on volume of 217,326,595 shares GameStop Corporation (GME) rose 47.5% to $46.55 on volume of 178,...
2024-06-05 16:38:33 ET More on Ventyx Biosciences Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Call Transcript Ventyx Pivots To Obesity Amid Transformation Ventyx Biosciences gets new operations chief Ventyx Biosciences drops 3%, stockholders to sell ~11....
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semag...
2024-05-16 08:36:00 ET More on Ventyx Biosciences Ventyx Pivots To Obesity Amid Transformation Ventyx Biosciences drops 3%, stockholders to sell ~11.17M shares Ventyx rebounds as Oppenheimer upgrades after pipeline updates Seeking Alpha’s Quant Rating ...
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...
2024-05-11 13:58:07 ET Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Conference Call May 9, 2024 16:30 ET Company Participants Martin Auster - Chief Financial Officer Raju Mohan - Founder and Chief Executive Officer John Nuss - Chief Scientific Officer C...
2024-05-09 16:04:01 ET More on Ventyx Biosciences Ventyx Pivots To Obesity Amid Transformation Ventyx Biosciences drops 3%, stockholders to sell ~11.17M shares Ventyx rebounds as Oppenheimer upgrades after pipeline updates Seeking Alpha’s Quant Rating ...
News, Short Squeeze, Breakout and More Instantly...
Ventyx Biosciences Inc. Company Name:
VTYX Stock Symbol:
NASDAQ Market:
Ventyx Biosciences Inc. Website:
A look at the top 10 most actives in the United States Freight Technologies Inc. (FRGT) rose 10.4% to $0.6899 on volume of 220,478,071 shares Nauticus Robotics Inc. (KITT) rose 23.2% to $0.17 on volume of 217,326,595 shares GameStop Corporation (GME) rose 47.5% to $46.55 on volume of 178,...
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semag...
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...